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Abstract: Nanocomposites as drug delivery systems (e.g., metal nanoparticles) are being exploited 
for several applications in the biomedical field, from therapeutics to diagnostics. Green 
nanocomposites stand for nanoparticles of biocompatible, biodegradable and non-toxic profiles. 
When using metal nanoparticles for drug delivery, the question of how hazardous these “virus-
sized particles” can be is posed, due to their nanometer size range with enhanced reactivity 
compared to their respective bulk counterparts. These structures exhibit a high risk of being 
internalized by cells and interacting with the genetic material, with the possibility of inducing DNA 
damage. The Comet Assay, or Single-Cell Gel Electrophoresis (SCGE), stands out for its capacity to 
detect DNA strand breaks in eukaryotic cells. It has huge potential in the genotoxicity assessment 
of nanoparticles and respective cells’ interactions. In this review, the Comet assay is described, 
discussing several examples of its application in the genotoxicity evaluation of nanoparticles 
commonly administered in a set of routes (oral, skin, inhaled, ocular and parenteral administration). 
In the nanoparticles boom era, where guidelines for their evaluation are still very limited, it is urgent 
to ensure their safety, alongside their quality and efficacy. Comet assay or SCGE can be considered 
an essential tool and a reliable source to achieve a better nanotoxicology assessment of metal 
nanoparticles used in drug delivery. 
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Nanocomposites as nanoparticulate delivery systems are playing a major role in the 
development of new drug formulations, as they can deliver a substance to the target with 
higher efficiency and precision than conventional forms, avoiding possible undesirable 
effects [1]. Other attributes, such as the potential use as theragnostic agents, have also been 
described [1,2]. However, a new concern has been raised as a consequence of the growing 
production and application of nanoparticles in drug delivery. “Nanotoxicology”, how 
dangerous nanoparticles can be? “Small” also means that nanoparticles can reach places 
that other larger particles cannot, such as the cellular core, where DNA is, which implies 
that they may interact with genetic material [3]. While the use of nanoparticles can be 
applied for DNA damage to remove neoplastic cells and cause cell death, miss-repaired 
damage or the occurrence of other nanoparticle interactions with the genetic material can 
alter the cells’ functions and interfere with the synthesis of proteins, which may cause 
potential diseases or even lead to carcinogenicity [4]. 
Genetic material-related toxicity is known as “genotoxicity” and the potential of 
nanoparticles to induce genotoxicity can be considered a primary (direct or indirect) or a 
secondary interaction. The genotoxicity effect can be direct if the nanoparticles exhibit the 
capacity to reach the nucleus and cause lesions directly in the genetic material. Indirect 
damage happens due to their capacity to induce oxidative stress which can cause 
genotoxicity. Secondary DNA damage may occur, for example, due to the capacity of 
macrophages and/or neutrophils to cause an inflammatory response, which is based 
essentially on the release of inflammatory cytokines, causing cellular lesions that can be 
reflected in the integrity of genetic material [5]. 
Despite the increasing research focusing on this topic, studies are still very limited 
and possible hazardous effects associated with nanoparticles are still unknown [6]. 
Therefore, efforts are currently being made to further assess their safety, especially 
because these “virus-sized particles” are in continuous contact with humans daily [7]. 
While official guidelines for evaluating the safety of nanoparticles are still somewhat 
limited, regulatory authorities have been making an effort to implement 
recommendations on nanotoxicology assessment [8]. Genotoxicity tests are an extremely 
important portion of this assessment. Among the available tests, the Comet Assay is 
currently in use both in vitro and in vivo to measure genotoxicity. It is already considered 
a powerful and promising tool for assessing DNA damage in clinical research and a 
standard application in the pharmaceutical industry for the evaluation of the safety profile 
of new drug formulations [9–11]. This assay was not specifically designed for 
nanoparticles [12], but its potential to explore their genotoxicity assessment is mentioned 
by several authors. Numerous organizations recommend the comet assay. In 2014, the 
OECD (Organization for Economic Co-Operation and Development) created the 489 
guideline for the “In vivo Mammalian Alkaline Comet Assay”, which describes the 
method in detail, as well its limitations and considerations, historical control data, and 
other information to consider [13]. The International Conference on Harmonization of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) also 
recommends its practice, among other assays, for a broader in vivo assessment [14]. 
Additionally, the European Food Safety Authority (EFSA) recognizes the importance of 
this assay, and it is recommended as a suitable approach by the Registration, Evaluation 
Authorization, and Restriction of Chemicals program of the European Commission 
[12,14]. 
Although an in vitro comet assay is not yet included in regulatory assessment toxicity 
guidelines, investments are being made to validate its use. Attributed to its versatility, 
robustness and reliability, it is likely to be included in a test battery for genotoxicity 
assessment [12]. 
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2. The Comet Assay 
The single-cell gel electrophoresis (SCGE), commonly known as comet assay, 
measures DNA strand breaks, at the level of individual eukaryotic cells [15]. It is a simple 
and sensitive method, frequently performed in animal cells, whether in culture or isolated 
from the organism, however, examination of DNA damage in plant cells is also possible 
[16]. This procedure, developed by Östling and Johanson (1984) and then adapted and 
optimized by Singh et al. (1988), is being considered one of the standard methods, not 
only for assessing DNA damage, with applications in human biomonitoring, genotoxicity 
testing, molecular epidemiology and ecotoxicology [15,17], but also to evaluate the DNA 
repair ability of cells [12], since the incubation of a damaging agent with cells can be 
monitored by measuring the damage remaining at intervals [15]. 
Depending on the literature and according to the purpose of this procedure, there are 
several ways of performing it, but the method most commonly used is the alkaline comet 
assay (Singh et al. procedure), for being the most sensitive in terms of detecting strand 
breaks of DNA, compared to the neutral one (Östling and Johanson procedure) [9]. 
Essentially, the alkaline process (pH > 13) detects not only single-strand breaks (SSBs) and 
double-strand breaks (DSBs) and even alkali labile sites (ALSs), but also, through the 
combination of specific endonucleases, particular base lesions [9]. Neutral SCGE only 
detects DSBs. 
The alkaline comet assay is a very sensitive method, as it detects low levels of DNA 
damage [18], however, several other advantages such as the requirement for small 
numbers of cells per sample, low cost, flexibility, performance facility and short assay 
execution time characterize this procedure [19]. Additionally, this assay considers both 
DNA content and DNA damage, allowing the measurement of the damage at any phase 
of the cell cycle [13]. 
The principle of the comet assay, shown in Figure 1, consists in incorporating cells in 
agarose gel layers on microscope slides, placing them in the presence of high salts 
concentration and detergents to occur the lysis of the cells, generating “nucleoids”. At this 
point, DNA organization consists of negatively supercoiled loops anchored to a residual 
proteinaceous nuclear matrix network, which later are exposed to high pH, to allow DNA 
to unwind. After this step, alkaline electrophoresis is carried out [9], attracting DNA 
nucleoids to the anode, but only DNA strands containing breaks migrate in the direction 
of the electrophoresis anode, generating comet-like shapes, giving the name to the assay 
[15,20]. The comet’s “head” contains undamaged DNA unlike the comet’s “tail” which 
contains damaged/relaxed DNA, which can be observed, usually, through fluorescence 
microscopy. Several authors argue that there is a direct proportion between the degree of 
intensity of the comet “tail” and the amount of DNA strand breaks existing in the 
individual cells [15]. 




Figure 1. The principle of the comet assay [own drawing]. The alkaline comet assay is mainly consisted of seven steps, 
including preparation of the microscope slides (1), suspension of cells (2), lysis of cells (3), exposure to alkali (pH > 13) and 
electrophoresis (4), neutralization of alkali (5), DNA staining (6) and finally, comet visualization and scoring (7). 
The alkaline comet assay is mainly based on seven steps, namely, preparation of the 
microscope slides, lysis of cells, exposure to alkali (pH > 13), electrophoresis (pH > 13), 
neutralization of alkali, DNA staining and comet visualization, and finally the comet 
scoring. 
2.1. Preparation of the Slides for Microscopy 
The procedure begins with the preparation of the microscope slides, with the 
previously prepared suspension of cells to be analyzed. This step is performed to obtain 
the gels that should be enough stable to survive through the analysis, as well as to facilitate 
the visualization of the comets with a minimum background noise [19]. There are several 
techniques for the slides’ preparation, but they all involve embedding cells in agarose 
layers. Each slide can be prepared with one to three layers of one or two independent 
agarose gels [19]. 
The single-layer procedure consists in suspending cells in low melting-point agarose 
(generally 37 °C) and then placing them directly on the slide [19]. In the two-layers 
procedure, the slides are firstly pre-coated with a layer of regular agarose (these pre-
coated slides are commercially available) and then an agarose layer containing the cells is 
placed on that pre-coated slide [19]. This first-layer coat of agarose on the slide improves 
the attachment of subsequent agarose layers. In the three-layers procedure, the process is 
very similar to the two-layers, but the difference is that the third layer with a Low Melting 
Point (LMP) agarose is added to increase the distance between the gel surface and the 
layer containing the cells, as well to ensure that any residual holes are removed of the 
second agarose layer [19]. 
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There is a successful three-layers procedure that is known for generating stable gels 
and this success is mainly due to the concentration of the agarose gel as well the cells 
concentration [19]. The first layer, which is coating the microscope slide, usually has a 
concentration between 1% and 1.5% and it is dried at 40–50 °C [19]. The second layer, 
which contains the cells, is usually between 0.5% and 1% agarose concentrated, and it is 
added to the first a few days later. Finally, the third layer is at the same concentration as 
the second [19]. Usually, only a few cells are needed to perform the Comet Assay because 
a higher density of cells can result in comets overlapping, compromising the image 
analysis. The extent of DNA migration can also be influenced by higher agarose 
concentrations [19]. 
2.2. Lysis of Cells 
This step consists of putting the agarose slides solidified in a lysis solution for the 
elimination of the membranes and to solubilize nuclear and cell constituents, forming the 
“nucleoids” (DNA attached to the nuclear matrix) [13]. Generally, the slides are in the 
solution (lysis buffer) for at least one hour, at 4 °C [13], but this period depends on the cell 
type. This lysis solution is composed of highly concentrated salts and detergents (e.g., 
EDTA, Sodium Chloride, DMSO, Triton X-100) and its composition also depends on the 
cell type. There are different types of lysis solutions according to different authors [19]. 
2.3. Alkali Unwinding 
At the end of the lysis, the “nucleoids” comprising DNA at a highly condensed state 
[13] are incubated with an alkaline (pH > 13) electrophoresis buffer (EDTA and Sodium 
Hydroxide, pH > 13) [19] in order to produce single-stranded DNA and to express ALSs 
as SSBs. For most of the purposes, it is demonstrated that 20 min are enough for alkali 
unwinding, but this length of time varies between studies and among researchers [19]. 
2.4. Electrophoresis 
After alkali unwinding, the next step is the electrophoresis under alkaline conditions, 
using the same pH buffer as the previous step. Usually, it is performed for a short period 
of time (20 to 30 min) [13] and conducted at the temperature of 5 °C to room temperature, 
depending on the cell type and the finality of the experiment, although the use of lower 
temperatures is thought to provide reproducibility increasing [19]. The typical voltages 
for electrophoresis are low, with the recommended voltage gradient ranging from about 
0.5 to 1.47 V/cm [18]. 
2.5. Neutralization of Alkali 
After electrophoresis, the neutralization step occurs, which consists in neutralizing 
the alkali in the gels with an appropriated buffer (e.g., PBS) [13]. Usually, three washes of 
the slides with the buffer are sufficient but if a high background is seen during scoring, 
additional rinsing may be beneficial [19]. After the neutralization, comets can be scored 
immediately or later, when convenient. However, slides should be scored with a 
reasonable length of time (e.g., 24 h) to prevent DNA excessive diffusion in the gel [19]. 
2.6. Staining of DNA and Visualization of the Comets 
DNA staining is usually performed with fluorescent dyes, such as ethidium bromide 
(one of the most commonly used [15]) or 4′,6-diamidine-2′-phenyl indole dihydrochloride 
(DAPI), followed by visualization in fluorescence microscopy. However, this selection 
largely depends on the researcher’s specific needs and, depending on the dye (e.g., 
Ethidium bromide, SYBR Gold, SYBR Green I and II, SYBR Safe, Eva Green) [21], certain 
types of DNA strand breaks can be better visualized [15]. Table 1 shows different dyes 
and their use in visualizing the certain DNA strand breaks. Then, the fluorescence can be 
measured on a fluorescence microscope equipped with specific detectors or a digital 
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camera [13]. Non-fluorescent techniques for comets visualization include staining DNA 
with silver nitrate [19], which demonstrated to increase the sensitivity/reproducibility of 
the assay when compared to the fluorescent staining [18]. Furthermore, it is also 
recommended to perform scanning of the gel so that the comets can be selected. This 
selection is very important because those comets will represent the whole gel, therefore, 
this procedure should be as narrow as possible [19]. The presence of comets around areas 
with air bubbles should be avoided, as well as comets with big tails and increased density 
of cells in the agarose (gels should have less than 2 × 104 cells) [15]. Variability in the 
imaging and analysis of comet assay samples may result from variations encountered in 
the protocol implemented to process the cells, the system used form capture microscope 
images and the software for computerized analysis [22]. 
Table 1. Brief characterization of several dyes used for the visualization of the DNA strand breaks (modified after [23]). 
Name of Dye Characterization Uses for Staining DNA 
Ethidium bromide 
- the most well-known dye used for 
visualizing DNA, 
- it can be used in the gel mixture, the 
electrophoresis buffer, or to stain the gel 
after it is run 
- molecules of the dye adhere to DNA 
strands and fluoresce under UV light, 
showing where the bands are within the gel 
SYBR Gold 
- more sensitive than ethidium bromide 
- used to stain double or single-stranded 
DNA  
- used to stain RNA 
- the dye binds to nucleic acids showing 
high UV fluorescence 
SYBR Green I 
- may be mutagenic because they bind to 
DNA 
- more sensitive for double-stranded DNA  
- requires careful handling 
- it fluoresces under UV light 
SYBR Green II 
- may be mutagenic because they bind to 
DNA 
- more sensitive for single-stranded DNA 
or RNA 
- requires careful handling 
- it fluoresces under UV light 
SYBR Safe 
- it is less toxic on several human cells that 
other dyes 
- it can be used with a blue light which 
causes less DNA damage 
Eva Green 
- suitable for low-melting-point gels 
- it shows very low or no cytotoxicity 
- it shows no mutagenicity 
- it shows low fluorescence alone but high 
fluorescence when bound to DNA 
2.7. Comet Scoring 
There are several different software packages and methods for quantifying the 
migration of the DNA by this assay. An image analysis technique for individual cells is a 
very suitable approach for comet scoring and analysis [13,18]. However, other systems are 
as useful [19], such as tail length, the relative fluorescence intensity of tail (normally 
expressed as % of DNA in the tail), and tail moment, whose parameters are not based on 
image analysis [15]. 
The most useful parameter applied is the relative fluorescence tail intensity as it gives 
a clear indication of what the comets actually looks like and it represents the intensity of 
the comet tail relative to the total intensity (head plus tail) [13]. Additionally, it allows 
discrimination of damage over the widest possible range, it is relatively unaffected by 
threshold settings and it reflects a linear correlation with break frequency [15]. The tail 
length is defined as the distance from the center of gravity of the nucleus, i.e., the position 
of the maximum fluorescence intensity over the nucleus, to the end of the tail. The tail 
moment is defined, essentially, as the product of DNA in the tail and the tail intensity [10]. 
Materials 2021, 14, 6551 7 of 17 
 
 
However, these procedures are not as recommended as relative fluorescence tail intensity 
[15]. 
Another approach consists in evaluating comets’ appearance, directly through 
observation with the human eye (visual scoring), in five levels of damage, from zero (no 
tail) up to four (in which most of the DNA is present in the tail) gives enough resolution 
[15]. It is also a fast and simple method, which can be a suitable choice if the aim is to 
avoid expensive methods [19]. It was demonstrated that computer scores and visual 
scores have a high correlation between them [15]. 
3. Limitations of Comet Assay and Toxicological Assessment 
There are still some factors that may create doubts about using comet assay to 
evaluate nanoparticles genotoxicity. Comet assay was firstly developed to detect DNA 
damage induced by soluble chemicals, and what happens is that nanoparticles are not 
removed, remaining during the assay [16]. Therefore, it is thought that nanoparticles can 
generate false levels of damage and that their presence within the nucleoid could affect 
DNA migration, as they are present in or in contact with cells, during the comet assay [16]. 
Ferraro et al. addressed this concern, by running the assay in the isolated nuclei instead 
of in the whole cells and concluded that this method resulted in an approximated result 
of the degree of genotoxicity induced by the nanoparticles, compared to the conventional 
one [16]. However, recent studies have shown that comet assays in vivo may even be 
superior to the well-established micronucleus erythrocyte assay as it can be applicable to 
any organ [24]. 
Nanotoxicology emerged as a multidisciplinary science [25–27], attributed to the 
urgency in evaluating the potentially harmful effects of nanoscale materials to biological 
systems, as well as the severity and frequency associated with the organisms and 
environment exposure to nanomaterials [28,29]. This need resulted from the fact that 
physical and chemical properties of nanoparticles are different from the respective bulk 
materials [30], together with the market growth of these materials [31]. 
There are several parameters that can affect the nanotoxicity profile of drug carriers 
but the most relevant ones are the size, shape and surface area, the surface characteristics, 
their stability, the impurities that compose the raw materials as well as their 
manufacturing methods, and the routes of exposure [32–36]. The size and surface area of 
nanocomposites are characteristics that have a huge impact on how they interact with cells 
because studies indicate that the higher the reduction of their size, the more toxic and 
reactive they become [37]. This happens because an increase in the superficial area/volume 
ratio occurs and consequently the risk of interacting with cellular organelles becomes 
bigger [37]. Therefore, nanoparticles with smaller dimensions have a higher capacity to, 
for example, reach the cells core and the increased possibility to interact with DNA, being 
more likely to cause DNA damage. 
In terms of route of exposure, there are different barriers that a nanoparticle 
formulation needs to overcome, in order to achieve the target. Since the comet assay is a 
straightforward approach for nanoparticles genotoxicity testing in cells, its application in 
the nanotoxicology assessment field is becoming more frequent [38]. To demonstrate its 
continuous increasing practice, several studies on different types of nanoparticles are 
summarized in Table 2. 
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Table 2. Examples of metal nanoparticles assessed by Comet assay for their risk of genotoxicity. 
Type of 
Nanoparticles 




0.5, 2 and 10 μg/mL CeO2 NPs of 
175.3 ± 10.2 nm tested in salivary 
leucocytes 
Increased primary and oxidative damage; no changes in 
DNA migration during electrophoresis, either by 
inducing additional breaks into the naked DNA or 





30, 50 and 90 nm (1–10 μg/mL) 
AuNPs tested in tumoral human 
leukaemia cells (HL-60) and 
human hepatoma cells (HepG2) 
In both cell lines, pyrimidines and purines were 
oxidatively damaged by all AuNPs, being 90 nm 
AuNPs slightly more genotoxic, using a endonuclease 
III and formamidopyrimidine-DNA glycosylase 
restriction enzymes modified comet assay 
[40] 
Carboxylate-, ammonium- or 
poly(ethylene glycol-
functionalized Au NPs cores of 
~5 nm and ~20 nm mean size 
tested in human bronchial 
epithelial BEAS-2B cells 
Cationic ammonium AuNPs were more cytotoxic than 
their anionic (carboxylate) and neutral (PEG)- 
functionalized AuNPs; 20-nm ammonium and 
PEGylated AuNPs induced DNA damage, while 
micronucleus induction was increased by 5-nm 





10 nm NPs at 200 μg/mL tested 
in TK6 cells  
TiO2-NPs were taken up by TK6 cells without 
significant induction of DNA breakage or oxidative 
DNA damage using the standard alkaline Comet assay 
and the endonuclease III (EndoIII) and human 8-
hydroxyguanine DNA-glycosylase (hOGG1)-modified 
Comet assay 
[42] 
80, 120 and 150 μg/mL TiO2 NPs 
of 199.1 ± 2.6 nm tested in 
salivary leucocytes 
Increased primary and oxidative damage; no changes in 
DNA migration during electrophoresis, either by 
inducing additional breaks into the naked DNA or 





20, 30 and 40 μg/mL ZnO NPs of 
485.6 ± 26.3 nm tested in salivary 
leucocytes 
Increased primary and oxidative damage; no changes in 
DNA migration during electrophoresis, either by 
inducing additional breaks into the naked DNA or 
inhibiting DNA migration 
[39] 
4. Evaluation of Genotoxicity of Metal Nanoparticles according to the Administration 
Route 
4.1. Oral Administration 
Oral nanoformulations for drug delivery are commonly used to protect drugs from 
proteolysis or to formulate poorly water-soluble drugs with the aim to increase their 
bioavailability through the gastrointestinal tract [43]. These nanoparticles can suffer 
systemic absorption and be captured by macrophages, that are present in many organs, 
e.g., liver, spleen, and kidneys, where nanoparticles can accumulate and cause toxicity 
[44]. Since the liver is the organ where the first-pass metabolism occurs, it is particularly 
vulnerable to the toxicity induced by nanoparticles, as these carriers can easily accumulate 
there, even long after risk of exposure [45]. On the other side, it has already been described 
that those nanoparticles can also be absorbed through the gastrointestinal tract via the 
lymph nodes, thereby undergoing transmigration to the liver and spleen [46–48]. The 
gastrointestinal tract can also be affected by the accumulation of nanoparticles [49]. Some 
experimental models commonly incorporated in the studying of the toxicity of ingested 
nanoparticles include intestinal epithelium cells (e.g., Caco-2, HT29, and SW480) [45]. 
Despite these characteristics, there is still limited information about their 
toxicological profile. Iglesias et al. evaluated the capacity of two types of poly(anhydride) 
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nanocomposites, namely Gantrez® AN 119-NP (GN-NPs) and Gantrez® AN 119 covered 
with mannosamine (GN-MA-NPs), and their main bulk material (Gantrez® AN 119-
Polymer), to induce DNA damage in L5178Y TK+/− mouse lymphoma cells, after 24 h of 
exposure to different concentrations [50]. In order to evaluate the possible genotoxicity of 
these nanoparticles and bulk material, the comet assay was performed in combination 
with formamidopyrimidine glycosylase (FPG), with the aim to check the presence of 
altered bases, DNA strand breaks (SBs) and alkali-labile sites (ALS) [50]. The 250 nm-sized 
particles, of negative surface charge and polydispersity index below 0.2 were not 
genotoxic to Caco-2 cells. Results showed that GN-NPs and GN-MA-NPs did not induce 
significant SBs nor ALS and FPG-sensitive sites in mouse lymphoma cells, which were 
shown to be more sensitive to nanoparticles than Caco-2 cells. On the other hand, the GN-
Polymer was more effective in increasing the sensitivity to FPG, at the highest tested 
concentration (600 μg/mL) [50]. These findings allow the confirmation of the oral safety 
profile of the empty poly(anhydride) nanocomposites, by genotoxicity evaluation [50]. 
Magnesium oxide nanoparticles (MgO-NPs) are very attractive due to their unique 
properties, extensive applications and chemical stability. However, despite these 
characteristics, there is still limited knowledge about their safety profile and human health 
impact [51]. Mangalampalli et al. studied the in vivo acute toxicity of MgO-NPs and MgO 
microparticles (MgO-MPs) intended for oral delivery in female albino Wistar rats together 
with the genotoxicity assessment using the Comet assay [51]. Both types of particles 
presented an average size of 53 nm and 12 μm, respectively. The rats were treated with 
increasing dosages of these particles (100, 500, and 1000 mg/kg). The whole blood was 
withdrawn from the retro-orbital plexus of the animals, at various sampling times (24 h 
and 72 h), and liver tissues were isolated after sacrificing [51]. Peripheral blood 
lymphocytes (PBL) and liver cells were analyzed through the alkaline comet assay, 
showing that both of them presented a significant increase in % tail DNA at 1000 mg/kg 
dose of MgO-NPs, at the 24 h and 72 h sampling times. At the dose of 500 mg/kg, the 
MgO-NPs induced a significant % tail DNA at both sampling time-points in liver cells, 
whereas in PBL were only at the 24 h sampling time. When administering MgO-MPs, no 
significant damage was observed in all tested doses. Additionally, a gradual reduction of 
the % tail DNA was observed over time, attributed to the mechanisms involved in the 
complex DNA repair [51]. This study confirms that particles size is a very important 
characteristic from a toxicological standpoint, as it showed that nanoparticles induced 
higher genotoxicity than microparticles. 
4.2. Skin Administration 
The skin is one of the largest organs of the body and functions as a primary barrier 
between the external surroundings and the internal organs [45], becoming, therefore, an 
important route for contact with nanoparticles [52]. 
Nanoparticles are applied topically, they can potentially penetrate the skin, reach the 
blood circulation, and induce adverse side effects [45]. However, research has shown that 
nanoparticles typically do not penetrate into the dermal layers, which demonstrates that 
in intact skin it is unlikely for nanoparticles to penetrate the deeper layers of the skin. If 
the skin is however compromised with lesions on the surface, it is highly probable that 
nanoparticles can reach the blood circulation [53–55]. 
The toxicity of nanoparticles that enter the body through the dermal route is normally 
studied in fibroblasts, keratinocytes, and, more rarely, sebocytes (cells of sebaceous 
glands) [45]. 
Titanium dioxide nanoparticles (TiO2) are worldwide used in several areas, including 
as a coating material in pharmaceutical nanocomposites [52]. Furthermore, their 
properties make them very appealing as an ingredient for sunscreens and other cosmetic 
formulations, as these nanoparticles have UV-light blocking abilities, offer higher 
transparency, and better appearance to creams [45,52]. Amongst the potential exposure 
routes, nasal and skin exposure are considered the most relevant for NPs. Several studies 
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clearly document that TiO2 nanoparticles can induce oxidative stress and DNA damage, 
as genotoxicity cellular effects [52,56]. 
Shukla et al. used human epidermal cells to evaluate the cytotoxicity, genotoxicity, 
and uptake of TiO2 [52]. The cells were exposed for 6 h to different concentrations of TiO2 
nanoparticles suspension, to detect oxidative DNA damage in specific bases. The results 
showed that the DNA damage was enhanced at the three highest tested concentrations 
(0.8, 8, and 80 μg/mL) [52]. In commercial sunscreens, the concentration of TiO2 
nanoparticles is commonly higher than the tested concentrations; however, considering 
that nanoparticles may remain onto the skin surface even after the formulation is cleaned 
up from the skin, the remaining particles can enter into this tissue and cause some 
damage. This study demonstrated that TiO2 nanoparticles may induce genotoxicity in 
human epidermal cells [52]. 
As happens with TiO2 nanoparticles, Zinc Oxide (ZnO) nanoparticles are widely 
employed in several industries, including cosmetics, personal care products and 
sunscreens, mainly due to their ultra-violet (UV) light absorption and antimicrobial 
properties [57,58]. ZnO nanoparticles constitute a type of metal oxide nanoparticles with 
promising applications in cell imaging, drug targeting and delivery. Their photocatalytic 
and photo-oxidizing properties against chemical and biological species, make these 
particles very appealing to figure in cosmetics, as food additives and in personal hygiene 
products. Additionally, zinc is proven to stimulate the immune system and demonstrated 
anti-inflammatory abilities. Recent studies showed that ZnO nanoparticles can induce 
cytotoxicity effects, followed by oxidative stress and genotoxicity, in leukemia and 
hepatocarcinoma cells in vitro, suggesting their application for the treatment of cancer 
therapy [59]. 
Studies demonstrate that ZnO nanoparticles are highly reactive compared to their 
bulk-sized materials, having those properties enhanced and may induce oxidative stress 
and genotoxicity in human cells. The fact that these nanoparticles are present in 
sunscreens (generally between 4 and 30 wt%) and exposed to UV radiation, along with 
the fact that they may induce ROS generation, encouraged Pal et al. to investigate the 
capacity of ZnO nanoparticles to induce DNA damage in primary mouse keratinocytes 
(PMKs), along with UVB-exposure [57]. ZnO nanoparticles of 32 nm of mean size and zeta 
potential of −9.21 mV, were in contact with PMKs for 24 h, at the concentration of 1 μg/mL. 
The comet assay was carried out in PMKs exposed to UVB alone, to ZnO nanoparticles 
alone, and to a combination of both. Results showed that tail moments value was greater 
in the combination groups compared to ZnO nanoparticles and UVB alone [57]. Sharma 
et al. evaluated the genotoxicity of ZnO nanoparticles of 30 nm of mean size and −15.8 mV 
of surface electrical (zeta potential) on the most abundant cell type in human epidermis 
i.e., primary human epidermal keratinocyte. At the tested concentration of 14 μg/mL ZnO 
nanoparticles induced significant genotoxicity on those cells, when in contact for 6 h [60]. 
Quantum dots (QDs) are fluorescent semiconductor crystals composed of a 
semiconductor inorganic core, an inorganic shell, and an aqueous organic coating. This 
latter improves their water solubility, stability and bioactivity [61,62]. Their diameter is 
usually between 1 and 10 nm, and the core is composed of metal elements from the groups 
II-V, with Cadmium as one of the most commonly used elements [61–63]. 
Several studies demonstrate that Cd is highly toxic and with the capacity to induce 
ROS formation, DNA damage and cell death [64,65]. 
To study the genotoxic risk of QDs, Ju et al. used the neutral comet assay on QDs of 
two different sizes, 4–5 nm (QDs with a core/shell of CdSe/ZnS) and 8–10 nm (QDs with 
a core/shell of CdSe/ZnS coated with a PEG thin-layer). The study aimed to check the 
effect of the PEG coating on the induction of DNA damage compared to the non-coated 
QDs. The sizes were also according to the commonly available size range. Other studies 
have shown that nanotoxicity is dependent on the surface properties of nanocarriers; PEG-
coating on QDs could be an approach to decrease their toxicity [61]. The uncoated QDs 
and PEG-QDs of two distinct sizes were applied at the concentrations of 8 nM and 80 nM, 
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in human skin fibroblasts for 8 h. After 2 h of exposure, uncoated QDs induced significant 
DSBs at both concentrations, with an increase in the tail moment at the highest 
concentration, while PEG-QDs showed no significant changes in results of the tail 
moment, compared to the control [61]. These outcomes encourage the fact that a proper 
surface modification in QDs can make a difference in their interaction with skin cells. In 
fact, the PEG-coating layer may prevent cadmium leakage, thereby reducing the 
generation of ROS by QDs and therefore reducing possible genotoxicity induction. 
Moreover, the uncoated QDs induce genotoxicity in a dose- and time-dependent manner. 
The long-term exposure to QDs still requires further investigation [61]. 
4.3. Pulmonary Administration 
The first-pass metabolism can avoid the systemic side effects when using the 
pulmonary route for systemic drug delivery [45]. However, because of their large surface 
area, nanoparticles may enhance the risk of inducing toxicity over non-loaded drugs, as 
the particles can accumulate in the lung tissue to a large extent. Studies have shown that 
nanoparticles with the size of about 50 nm can lead to membrane perforation of type 1 
alveolar cells, resulting in nanoparticles internalization in these cells [45]. The toxicity of 
inhaled nanoparticles is commonly studied using model cell lines that differ from 
respiratory system tissues, e.g., A459 and C10 cells of pulmonary origin, alveolar 
macrophages, various epithelial cells and fibroblasts and also human monocytes, posing 
an additional problem on the assessment of the cyto-genotoxicity [45]. 
The International Agency for Research on Cancer has listed carbon black particles 
among the substances with the potential risk of carcinogenesis in humans and yet carbon 
black is applied largely in the chemical industry for the production of rubbers, toners, 
paints. There is therefore a risk of occupational exposure through inhalation of these 
particles during the handling of dry powders [66]. Studies have shown that carbon black 
nanoparticles have the capacity to induce ROS and cause DNA strand breaks in the lungs. 
Kyjovska et al. studied this possibility by administering, by intratracheal instillation, 
a single dose of 0.67, 2, 6, and 162 μg/animal of carbon black nanoparticles (size: 14 nm) 
to mice (8 mice for each dose). The animals were killed 1, 3 or 28 days after exposure to 
nanoparticles, and their lungs, liver and Broncho-Alveolar Lavage (BAL) were collected 
to run the alkaline comet assay [66]. The results demonstrate that there was DNA damage 
in the BAL, after one day of exposure to 0.67 and 2 μg/animal and it was significant for 
the 0.67, 2, and 6 μg/animal dose, 28 days post-exposure [66]. In the lungs, there was no 
significant DNA damage on the three lower concentration groups, after one day of 
exposure, but significant strand breaks were detected at the highest dose. After 28 days, 2 
and 6 μg/animal caused a significant increase in the level of DNA damage [66]. In the 
liver, no DNA damage was detected at any doses and time-points of exposure. A lack of 
dose-response relationship was reported in this study [66]. 
Gold nanoparticles (AuNPs) have been attracting scientific interest not only for the 
facilities in their synthesis and surface bioconjugation but also for their unusual optical, 
electronic, and thermal properties [67]. These nanoparticles have large medical 
applications. However, their possible nanotoxicity effects are still unknown [68]. Ng et al. 
studied the risk of AuNPs of 20 nm in inducing genotoxicity on small airway epithelial 
cells (SAECs), exposing these cells to concentrations of 1 nmol/L (equivalent to 48.65 
μg/mL) to AuNPs, through the in vitro alkaline comet assay, for 72 h [68]. DNA damage 
was observed at this concentration and demonstrated when compared to the control, a 
significant increase of the tail moment [68]. 
4.4. Ocular Administration 
One of the major challenges for drug delivery has been ocular administration, 
particularly when it comes to nanoformulations, due to intricate and unique anatomical 
and physiological barriers in the eye, that protect it from the invasions of microorganisms 
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and environmental toxicants, keeping the systemic circulation from the ocular tissues [69–
72]. 
These barriers make the eye a highly protected organ and therefore when an ocular 
disease occurs, it becomes very difficult to set a treatment, especially in the ocular 
posterior segment [70,71,73]. To treat this area, several delivery modalities have been 
applied, such as intravitreal injection, the most commonly applied method for posterior 
drug delivery. Subretinal injection, subconjunctival injection and topical administration 
are also used. However, these are not satisfactory since they are invasive procedures with 
serious associated risks. Therefore, a better approach is still required [69,74]. 
Current developments in nanoparticles drug delivery have become promising traits 
for the prolongation of the drug release and to enhance drug retention/permeation in 
ocular tissue, providing novel opportunities to overcome the limitations of conventional 
drug delivery systems [69]. 
Particles larger than 1 μm may potentially cause ocular irritation [70,71]. Therefore, 
nanoparticles for ocular installation may be an advantage to reduce the irritation of the 
eye, as well as to enhance the bioavailability of topical administration, achieve controlled 
release, targeted delivery, reduce the frequency of administration with improved patient 
compliance, and ultimately, improved therapeutics efficacy [69]. 
To explore the use of ZnO nanoparticles in ocular drug delivery and the risk of 
inducing genotoxicity in ocular tissue, Guo et al. performed a study, using a RGC-5 cell 
line, since the rat retinal ganglion cells were more susceptible to outer surroundings than 
other eye cells [59]. The cells were exposed to different concentrations of ZnO 
nanoparticles (0, 2.5, 5.0, and 10.0 μg/mL) of a mean size of 100 nm for a 6 h period. The 
results show that untreated cells had an intact nucleus, with no formed comets unlike the 
treated cells, for which the damage was increased with the increase of the concentration 
of ZnO nanoparticles [59]. 
Cerium oxide (CeO2) nanoparticles are known for their antioxidant and optical 
properties and for having a high affinity to oxygen. These nanoparticles may constitute a 
potential means for imaging and drug delivery to the ocular tissue for the treatment of 
e.g., cataract and glaucoma. Studies involving the effects of CeO2 nanoparticles on eye lens 
suggest that these particles may have a protective effect on the retina [75]. The outcomes 
of these nanoparticles in vivo are however not well known, since their application in 
medicine is a new field to be exploited. It is therefore mandatory to further characterize 
the possible toxicological effects of these particles in the eye (e.g., potential risk of DNA 
damage), as they can influence the formation of structural proteins and eye cells 
negatively, leading to potential diseases [75]. 
Pierscionek et al. use the alkaline comet assay in three replicated cultured human 
lens epithelial cells, incubating the cells with two sets of CeO2 nanoparticles of mean size 
of 5.5 nm, i.e., one set with the concentration of 5 μg/mL and the other set with the 
concentration of 10 μg/mL [75]. The comets were scored by % of DNA tail and head, tail 
length, and olive tail moment and results demonstrated a low level of DNA damage in all 
data sets. When applying the highest dose, there was a slight increase in the % of DNA 
tail, however, no statistical differences were recorded between control and treated cells 
for both tested concentrations [75]. 
4.5. Parenteral Administration 
Parenteral nanoparticles are applied as therapeutics and diagnostics, as drug carriers 
and contrast agents, respectively. Nano-intravenous administration is a very significant 
route used in defining toxicological profiles of nanoparticles, in biological assessment. 
Several studies established that there is a high probability of occurring deposition of 
nanoparticles in several organs through this type of exposure [76]. The toxicity of these 
particles is usually studied in primary blood cell cultures, mononuclear blood cells, 
cultured HUVECs, mesenchymal stem cells, and various tumor cell lines (HeLa, MCF-7, 
PC3, C4-2, and SKBR-3) [45]. 
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Silver nanoparticles (AgNPs) are amongst the most commercially used 
nanocomposites. These metallic nanoparticles have attracted technical interest and intense 
scientific due to the optical, electronic, and thermal properties that make these 
nanoparticles unique. The easy surface bioconjugation and synthesis make these systems 
very pleasant for drug delivery. They are well-known not only for being excellent 
antibacterial and antiviral agents but also for having a great performance as anti-
angiogenic agents, with applications in multiple myelomas, leukemia, and rheumatoid 
arthritis [77]. 
With the increasing use of AgNPs, their safety and potential risk to human health 
have been discussed and raised, therefore, scientific research is required to evaluate the 
potential toxicity and the genotoxicity of these nanoparticles [77]. 
Several in vivo studies, although in a limited quantity compared to the in vitro ones, 
have been carried out, in order to evaluate genotoxicity of AgNPs in the body tissues [77], 
as in vitro data alone may not be sufficient for genotoxicity assessment of nanocomposites 
[77]. It is reported that AgNPs might generate reactive oxygen species (ROS) when 
accumulated in the liver, causing hepatotoxicity [78]. 
Li et al. tested two in vivo types of silver nanoparticles (AgNPs), namely PVP-coated 
AgNPs (of 5 nm mean size) and silicon-coated AgNPs (of 10–80 nm mean size). Particles 
were administered intravenously to 7-week-old male mice (weighing 25–30 g). for three 
consecutive days to evaluate the possible effect of size and coating. Additional groups of 
mice served as negative and positive controls [77]. For both PVP- and Silicon-coated 
AgNPs, no DNA strand-breaks were detected in the liver when using the standard Comet 
Assay, while a significant induction of DNA damage was found in the enzyme-modified 
Comet Assay, with silicon being the most toxic to the cells. The addition of nuclease 
enzymes resulted in DNA breaks which suggest that AgNPs can cause oxidative DNA 
damage [77]. 
The genotoxicity of AgNPs in the liver of rabbits was tested by Kim et al. one week 
and one month after a single intravenous injection into the ear veins. The tested 
nanoparticles had a citrate coating (cAgNPs) which offers a negative charge on the 
particles’ surface. The size of cAgNPs was approximately 7.9 nm [78]. The suspensions of 
cAgNPs comprehended a low dose of 0.5 mg/kg and a high dose of 5 mg/kg that were 
given, respectively, to two groups of four rabbits. The results demonstrated that the 
damage of DNA in liver tissue was higher in the group of the 5 mg/kg dose than in the 0.5 
mg/kg. Plus, the DNA damage at day 28 declined compared to the damage at day 7, in 
the high-dose treated group, which reveals time- and dose-dependent variations in 
genotoxicity and oxidative stress, after a single injection of the tested particles [78]. 
TiO2 nanoparticles, as discussed above, are largely used in industry, and because of 
their multiple applications, it becomes necessary to investigate every possible form of 
these nanoparticles interacting with the human body and the possibility of inducing 
genotoxicity [79], as humans are being increasingly exposed by multiple routes [80]. The 
risk of these particles reaching the endothelium is almost inevitable and can occur before 
reaching other secondary organs, which can cause endothelial dysfunction and 
impairments, consequently affecting cardiovascular health [79,80]. 
Liao et al. investigated the effect of TiO2 nanoparticles on the cardiovascular system, 
evaluating the genotoxic potential of four sizes (100, 50, 30, and 10 nm) of TiO2 
nanoparticles in HUVECs, through the comet assay and exposing the nanoparticles to the 
cells through 4 h [79]. All the sizes demonstrated to induce DNA damage which decreased 
with the size increase of TiO2 nanoparticles, revealing the importance of studying the size 
effect on inducing cellular responses [79]. 
Iron oxide nanoparticles (IONPs) are being used in biomedicine due to their magnetic 
properties, possible use as carriers for gene delivery, and in cancer therapy. Ansari et al. 
performed the comet assay in vivo on male Wistar rats with the administration of IONPs 
through the intraperitoneal route, for 7 consecutive days. The animals were split into 9 
groups, each one with six animals. Three groups were studied with three different IONPs 
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concentrations (25, 50, and 100 mg/kg) respectively [81]. IONPs were characterized for 
their size and shape, showing that they had a spherical shape and an average size of 
approximately 60 nm [81]. In order to perform the comet assay on the lymphocytes of the 
rats, the animals were sacrificed, and their blood was freshly collected to isolate the cells 
for the assay [81]. Results showed that the average tail length increased with the increase 
of the IONPs concentration compared with the negative control, with the concentration of 
100 mg/kg having the higher average tail length. 
5. Conclusions 
Over the years, the diversity and the complexity of nanocomposites have been 
growing, however, the respective translation into the clinic has been limited. The possible 
causes for this limitation may be the lack of established characterization and testing 
regimes that can provide regulatory authorities (e.g., FDA, EMA) with the necessary data 
to allow novel nanocomposites reach the market. There are currently no tangible strict 
guidelines regarding toxicity testing for nanoparticles and, therefore, the implementation 
of new characterization technologies or the adaptation of currently available ones should 
be done in close interaction with regulatory authorities, to ensure that the new assimilated 
data on candidates will therefore allow novel nanomedicine to be part of healthcare 
advances and create a difference on a global scale. In general, the strategies used to 
evaluate the safety/toxicity and biocompatibility of nanocomposites have been adapted 
from the techniques applied in the testing of conventional drug products and, therefore, 
there is an urgency in proving that these methods are adaptable and viable for 
nanotoxicity evaluation. The same characteristics that make nanocomposites interesting 
for many applications are the same that lead to genotoxicity effects. The assessment of 
genotoxicity of nanoparticles can benefit from the comet assay, not only because of the 
characteristics of the assay but also because the current standardized practices used for 
assessing the genotoxicity of chemicals not always are proper for nanogenotoxicity 
assessment. According to OECD, an assay that identifies and characterizes DNA damage 
is required not only through direct interaction, detecting DNA strand breaks and altered 
DNA bases but also through indirect and secondary mechanisms as well (e.g., oxidative 
stress induced by inflammation). Comet assays meet these requirements and may 
therefore be a suitable approach to include in upcoming guidelines for nanotoxicity 
assessment. 
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